IS7296A - Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun - Google Patents

Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun

Info

Publication number: IS7296A
Authority: IS; Iceland
Prior art keywords: cop; vaccine; tyr; glu; poly
Prior art date: 2001-12-06

Application number

IS7296A

Other languages

English (en)

Other versions

IS2670B (is

Inventor

Eisenbach-Schwartz Michael

Yoles Esther

Original Assignee

Yeda Research And Development Co. Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2004-06-03

Publication date

2004-06-03

2004-06-03 Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.

2004-06-03 Publication of IS7296A publication Critical patent/IS7296A/is

2010-09-15 Publication of IS2670B publication Critical patent/IS2670B/is

Links

229960005486 vaccine Drugs 0.000 title abstract 2
230000004770 neurodegeneration Effects 0.000 title 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
208000026072 Motor neurone disease Diseases 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010061818 Disease progression Diseases 0.000 abstract 1
206010056677 Nerve degeneration Diseases 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000005750 disease progression Effects 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

IS7296A 2001-12-06 2004-06-03 Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun IS2670B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33613901P	2001-12-06	2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en)	2001-12-06	2002-12-05	Vaccine and method for treatment of motor neurone diseases

Publications (2)

Publication Number	Publication Date
IS7296A true IS7296A (is)	2004-06-03
IS2670B IS2670B (is)	2010-09-15

Family

ID=23314742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7296A IS2670B (is)	2001-12-06	2004-06-03	Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun

Country Status (23)

Country	Link
US (1)	US7351686B2 (is)
EP (1)	EP1429800B1 (is)
JP (1)	JP4542339B2 (is)
KR (1)	KR20040081431A (is)
CN (2)	CN1617736A (is)
AT (1)	ATE422362T1 (is)
AU (1)	AU2002353486B2 (is)
CA (1)	CA2469092C (is)
CY (1)	CY1109044T1 (is)
DE (1)	DE60231131D1 (is)
DK (1)	DK1429800T3 (is)
ES (1)	ES2322566T3 (is)
HU (1)	HU228207B1 (is)
IL (1)	IL160105A0 (is)
IS (1)	IS2670B (is)
MX (1)	MXPA04005537A (is)
NO (1)	NO336231B1 (is)
NZ (1)	NZ533356A (is)
PL (1)	PL205469B1 (is)
PT (1)	PT1429800E (is)
RU (1)	RU2303996C2 (is)
SI (1)	SI1429800T1 (is)
WO (1)	WO2003047500A2 (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399740B2 (en)	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy
CA2512735C (en) *	2003-01-07	2016-03-08	Yeda Research And Development Co. Ltd.	Eye-drop vaccine containing copolymer 1 for therapeutic immunization
EP2301569B1 (en)	2003-11-12	2018-05-02	Yeda Research and Development Co. Ltd.	Vaccine and method for treatment of neurodegenerative diseases
CA2548310C (en)	2003-12-09	2014-02-18	Yeda Research And Development Co. Ltd.	Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
AU2005218625A1 (en) *	2004-03-03	2005-09-15	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and riluzole
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
MXPA06012864A (es) *	2004-05-07	2007-07-18	Peptimmune Inc	Metodo de tratamiento de enfermedades con copolimeros aleatorios.
CA2615506A1 (en)	2005-07-15	2007-01-25	Novartis Ag	Pamps, pathogen associated molecular patterns
CN100448481C (zh) *	2006-06-22	2009-01-07	中国科学院遗传与发育生物学研究所	xCT蛋白及其编码基因的新用途
EP2195008A1 (en)	2007-09-24	2010-06-16	Hadasit Medical Research Services & Development Ltd.	Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2627669T3 (pl)	2010-10-11	2017-02-28	Teva Pharmaceutical Industries Ltd.	Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
EP2699317B1 (en)	2011-04-21	2016-08-10	Mapi Pharma Limited	Random pentapolymer for treatment of autoimmune diseases
EP2765857A4 (en)	2011-10-10	2015-12-09	Teva Pharma	SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
EP2788017B1 (en) *	2011-12-05	2017-05-31	Ben-Gurion University of The Negev Research and Development Authority	INHIBITORS OF IgG-A2BG2 FOR USE IN TREATING AND DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS
CA2907909A1 (en) *	2012-03-26	2013-10-03	Neuroquest Ltd.	Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
EP2892353A4 (en)	2012-09-10	2016-10-26	Yeda Res & Dev	INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en)	2016-08-31	2024-09-05	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
MX2019010174A (es)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
US3849650A (en)	1973-03-29	1974-11-19	Picker Corp	Automatic x-ray inspection system
US5800808A (en) *	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) *	1995-10-17	1997-08-04	Kenneth G Haglid	Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) *	1996-09-27	2003-09-10	Гилфорд Фармасьютикалз Инк.	Способ лечения глутаматных расстройств
AU2868699A (en) *	1998-02-13	1999-08-30	Autoimmune, Inc.	Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
US20020072493A1 (en)	1998-05-19	2002-06-13	Yeda Research And Development Co. Ltd.	Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en)	1998-05-19	2003-06-12	Michal Eisenbach-Schwartz	Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en)	1998-05-19	1999-11-25	Yeda Research And Development Co., Ltd.	Activated t cells, nervous system-specific antigens and their uses
EP1039929A1 (en)	1998-07-21	2000-10-04	YEDA RESEARCH AND DEVELOPMENT Co. Ltd.	Activated t-cells and their uses
CA2336238A1 (en)	1998-07-23	2000-02-03	The President And Fellows Of Harvard College	Synthetic peptides and methods of use for autoimmune disease therapies
RU2155063C1 (ru) *	1999-10-20	2000-08-27	Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии"	Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
ATE302020T1 (de)	2000-01-20	2005-09-15	Yeda Res & Dev	Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
ES2256200T3 (es)	2000-06-07	2006-07-16	Yeda Research And Development Co., Ltd.	El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato.
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) *	2001-06-28	2004-12-28	Yeda Research And Development Co. Ltd.	Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) *	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy

2002
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 EP EP02788511A patent/EP1429800B1/en not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown

Also Published As

Publication number	Publication date
CY1109044T1 (el)	2014-07-02
CA2469092A1 (en)	2003-06-12
NO20042833L (no)	2004-08-12
ES2322566T3 (es)	2009-06-23
RU2004120536A (ru)	2005-03-27
AU2002353486A1 (en)	2003-06-17
HUP0500039A3 (en)	2010-01-28
DK1429800T3 (da)	2009-04-27
SI1429800T1 (sl)	2009-08-31
WO2003047500A3 (en)	2004-03-18
EP1429800B1 (en)	2009-02-11
ATE422362T1 (de)	2009-02-15
CN1617736A (zh)	2005-05-18
HK1067043A1 (en)	2005-04-01
RU2303996C2 (ru)	2007-08-10
PT1429800E (pt)	2009-04-27
NO336231B1 (no)	2015-06-22
CN102151330A (zh)	2011-08-17
IL160105A0 (en)	2004-06-20
EP1429800A4 (en)	2006-03-22
DE60231131D1 (de)	2009-03-26
NZ533356A (en)	2006-10-27
KR20040081431A (ko)	2004-09-21
MXPA04005537A (es)	2004-11-01
CN102151330B (zh)	2017-04-12
JP4542339B2 (ja)	2010-09-15
IS2670B (is)	2010-09-15
PL205469B1 (pl)	2010-04-30
AU2002353486B2 (en)	2009-01-15
JP2005515198A (ja)	2005-05-26
US20050220802A1 (en)	2005-10-06
EP1429800A2 (en)	2004-06-23
HU228207B1 (hu)	2013-01-28
PL370070A1 (en)	2005-05-16
WO2003047500A2 (en)	2003-06-12
CA2469092C (en)	2013-02-19
HUP0500039A2 (hu)	2005-03-29
US7351686B2 (en)	2008-04-01

Publication	Publication Date	Title
IS7296A (is)	2004-06-03	Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
AU1879697A (en)	1997-09-16	Peptide immunogens for vaccination against and treatment of allergy
MXPA05002814A (es)	2005-05-27	Formulacion para agentes lipofilicos.
ATE504308T1 (de)	2011-04-15	Antimikrobielle kationische peptide und diese enthaltende formulierungen
AU2002236765A1 (en)	2002-07-30	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DK1409006T3 (da)	2011-06-14	Monodispergerede blandinger og fremgangsmåder til behandling af diabetes
MXPA03010085A (es)	2004-03-10	Composiciones y su uso en la hiperplasia.
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
MXPA02005563A (es)	2004-09-10	Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
AU7242796A (en)	1997-04-09	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1958960A3 (en)	2009-01-07	A process for the preparation of a non-toxic anthrax vaccine
SE9603725D0 (sv)	1996-10-11	New teatment
MXPA02010173A (es)	2003-06-04	Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
YU45103A (sh)	2006-08-17	Upotreba sarp/1 za lečenje i prevenciju skleroderme
UY27373A1 (es)	2003-02-28	Formulaciones de interferón beta-humano
PT1076561E (pt)	2005-08-31	Terapia de combinacao para o tratamento de tumores
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
SG142165A1 (en)	2008-05-28	Biologically active peptides
WO1998035045A3 (en)	1998-10-29	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
PT1150703E (pt)	2006-05-31	Terapia de esclerose multipla com chaperonina 10 e beta-interferao
DK0938329T3 (da)	2002-09-09	Immunogen TLP sammensætning
CA2394843A1 (en)	2001-05-31	A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
WO2002098359A3 (en)	2003-04-03	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1113073A3 (en)	2003-05-14	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis